Loading...
•
Mar 31, 2024
Aquestive Q1 2024 Earnings Report
Reported financial results for the first quarter and provided a business update.
Key Takeaways
Aquestive Therapeutics reported an 8% increase in total revenues to $12.1 million for Q1 2024, driven primarily by higher revenue from out-licensed products. The company highlighted the successful completion of the Anaphylm Phase 3 study and FDA approval for Libervant in patients aged 2-5, extending their cash runway into 2026.
Met all endpoints in Phase 3 pivotal study for Anaphylm™ when compared to EpiPen® and other injectors.
Received FDA approval and U.S. market access for Libervant™ in patients between ages two to five.
Extended cash runway into 2026 with completion of $77.5 million underwritten public offering.
Total revenues increased to $12.1 million, an 8% increase driven by higher revenue from out-licensed products.
Forward Guidance
Aquestive expects total revenue between $48 million and $51 million and a non-GAAP adjusted EBITDA loss between $22 million and $26 million for the full year 2024.
Historical Earnings Impact
Analyze how earnings announcements historically affect stock price performance
Avg. Return Before/After Earnings
Loading earnings performance data...
Loading earnings reaction data...